Literature DB >> 12417541

Potential role of autoantibodies belonging to the immunoglobulin G-3 subclass in cardiac dysfunction among patients with dilated cardiomyopathy.

Alexander Staudt1, Marko Böhm, Fabian Knebel, Yvonne Grosse, Claudia Bischoff, Astrid Hummel, Johannes B Dahm, Adrian Borges, Nicoline Jochmann, Klaus D Wernecke, Gerd Wallukat, Gert Baumann, Stephan B Felix.   

Abstract

BACKGROUND: Immunoadsorption capable of removing circulating autoantibodies represents an additional therapeutic approach in dilated cardiomyopathy (DCM). The role played by autoantibodies belonging to the immunoglobulin (Ig) subclass G-3 in cardiac dysfunction remains to be elucidated. METHODS AND
RESULTS: Patients with DCM (left ventricular ejection fraction <30%) participated in this case-control study. Nine patients underwent immunoadsorption with protein A (low affinity to IgG-3), and 9 patients were treated with anti-IgG, which removes all IgG subclasses. Immunoadsorption was performed in 4 courses at 1-month intervals until month 3. In the 2 groups, immunoadsorption induced comparable reduction of total IgG (>80%). IgG-3 was effectively eliminated only by anti-IgG adsorption (eg, during the first immunoadsorption course; protein A, -37+/-4%; anti-IgG, -89+/-3%; P<0.001 versus protein A). The beta1-receptor autoantibody was effectively reduced only by anti-IgG (P<0.01 versus protein A). Hemodynamics did not change in the protein A group. In the anti-IgG group during the first immunoadsorption course, cardiac index increased from 2.3+/-0.1 to 3.0+/-0.1 L x min(-1) x m(-2) (P<0.01 versus protein A). After 3 months, before the last immunoadsorption course, cardiac index was 2.2+/-0.1 L x min(-1) x m(-2) in the protein A group and 3.0+/-0.2 L x min(-1) x m(-2) in the anti-IgG group (P<0.01 versus protein A). Left ventricular ejection fraction increased only in the anti-IgG group (P<0.05 versus protein A).
CONCLUSIONS: Autoantibodies belonging to IgG-3 may play an important role in cardiac dysfunction of DCM. The removal of antibodies of the IgG-3 subclass may represent an essential mechanism of immunoadsorption in DCM.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12417541     DOI: 10.1161/01.cir.0000036746.49449.64

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  29 in total

Review 1.  The clinical significance of anti-beta-1 adrenergic receptor autoantibodies in cardiac disease.

Authors:  Udi Nussinovitch; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

2.  B-cell epitope spreading is a critical step for the switch from C-protein-induced myocarditis to dilated cardiomyopathy.

Authors:  Yoh Matsumoto; Il-Kwon Park; Kuniko Kohyama
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

3.  Immunoadsorption in a 40 year old man with dilated cardiomyopathy and underlying active myocarditis.

Authors:  Iris I Müller; Karin Klingel; Viacheslav O Nikolaev; R Jahns; Meinrad P Gawaz; Hans-Jörg Weig
Journal:  Clin Res Cardiol       Date:  2008-07-16       Impact factor: 5.460

4.  Very late-onset reversible cardiomyopathy in patients with chronic GvHD.

Authors:  H Kawano; H Tanaka; T Yamashita; K-I Hirata; S Ishii; T Suzuki; K Wakahashi; Y Kawano; A Sada; K Minagawa; F Kawakami; T Itoh; A Baba; T Matsui; Y Katayama
Journal:  Bone Marrow Transplant       Date:  2015-03-23       Impact factor: 5.483

5.  Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition.

Authors:  Sarah B Sunshine; Susan M Dallabrida; Ellen Durand; Nesreen S Ismail; Lauren Bazinet; Amy E Birsner; Regina Sohn; Sadakatsu Ikeda; William T Pu; Matthew H Kulke; Kashi Javaherian; David Zurakowski; Judah M Folkman; Maria Rupnick
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-25       Impact factor: 11.205

Review 6.  Autoantibodies and cardiovascular dysfunction: cause or consequence?

Authors:  Yuji Nagatomo; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2014-12

7.  Safety and Efficacy of Immunoadsorption as an Add-On to Medical Treatment in Patients with Severe Idiopathic Pulmonary Arterial Hypertension.

Authors:  Christian Nagel; Ralf Ewert; Benjamin Egenlauf; Hans B Lehmkuhl; Stephan Rosenkranz; Nicola Benjamin; Vedat Schwenger; Felix J F Herth; Ekkehard Grünig
Journal:  Respiration       Date:  2017-08-05       Impact factor: 3.580

Review 8.  Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives.

Authors:  Bernhard Maisch; Sabine Pankuweit
Journal:  Heart Fail Rev       Date:  2013-11       Impact factor: 4.214

9.  Analysis of specific Th1/Th2 helper cell responses and IgG subtype antibodies in anti-CD4 monoclonal antibody treated mice with autoimmune cardiomyopathy.

Authors:  Zhaohui Wang; Yuhua Liao; Jing Yuan; Jinghui Zhang; Jihua Dong; Jinping Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-08-15

10.  Immunoadsorption therapy for patients with dilated cardiomyopathy and heart failure.

Authors:  Uichi Ikeda; Hiroki Kasai; Atsushi Izawa; Jun Koyama; Yoshikazu Yazaki; Masafumi Takahashi; Makoto Higuchi; Chang-Sung Koh; Keiji Yamamoto
Journal:  Curr Cardiol Rev       Date:  2008-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.